Wockhardt receives USFDA approval for Cefotaxime injection

New Delhi, Aug 31 (UNI) Wockhardt Ltd today said it has received approval from the United States Food and Drug Administration (US FDA) for marketing Cefotaxime sodium (1 gm) injection in the US market.

Cefotaxime sodium is the generic version of Sanofi Aventis Claforan injection and is a broad-spectrum antibiotic used in treating a wide variety of infections.

''This is our second approval for sterile cephalosporins, and our sixth approval in the last eight months,'' said Wockhardt Chairman Habil Khorakiwala.

Wockhardt's US subsidiary, Wockhardt USA Inc, will launch this cephalosporin antibiotic in the US market within the next few weeks.

Cefotaxime sodium is manufactured at the US FDA certified sterile cephalosporin API (active pharmaceutical ingredient) facility at Ankleshwar, Gujarat, and the injection is manufactured at the sterile formulation plant at Walujin Maharashtra. The processes for both API and the injection were developed in-house.

The company currently markets 14 products in the US.

UNI CS VA BS1124